OBJECTIVE: We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans. METHODS AND RESULTS: Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148+/-0.049 versus 0.499+/-0.099 pools x d(-1); P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97+/-10.51 versus 21.32+/-4.21 mg x kg(-1) x d(-1), respectively; P=0.02). CONCLUSIONS: This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.
OBJECTIVE: We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans. METHODS AND RESULTS: Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148+/-0.049 versus 0.499+/-0.099 pools x d(-1); P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97+/-10.51 versus 21.32+/-4.21 mg x kg(-1) x d(-1), respectively; P=0.02). CONCLUSIONS: This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.
Authors: Michael E Lassman; Thomas McAvoy; Anita Y H Lee; Derek Chappell; Oitak Wong; Haihong Zhou; Gissette Reyes-Soffer; Henry N Ginsberg; John S Millar; Daniel J Rader; David E Gutstein; Omar Laterza Journal: Clin Chem Date: 2014-04-21 Impact factor: 8.327
Authors: Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger Journal: Clin J Am Soc Nephrol Date: 2013-04-18 Impact factor: 8.237
Authors: Haihong Zhou; Jose Castro-Perez; Michael E Lassman; Tiffany Thomas; Wenyu Li; Theresa McLaughlin; Xie Dan; Patricia Jumes; John A Wagner; David E Gutstein; Brian K Hubbard; Daniel J Rader; John S Millar; Henry N Ginsberg; Gissette Reyes-Soffer; Michele Cleary; Stephen F Previs; Thomas P Roddy Journal: Rapid Commun Mass Spectrom Date: 2013-06-30 Impact factor: 2.419
Authors: B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard Journal: Diabetologia Date: 2008-06-05 Impact factor: 10.122
Authors: Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts Journal: Clin Sci (Lond) Date: 2009-11-23 Impact factor: 6.124